Pertuzumab, Trastuzumab and Docetaxel in HER2-Positive metastatic breast cancer. NEJM 2015, 372: 724-34
Swain, S.M., et al.
http://www.nejm.org/doi/full/10.1056/NEJMoa1413513?af=R&rss=currentIssue
In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months.
